SHR 0302Alternative Names: SHR0302
Latest Information Update: 20 Sep 2016
$50 / €47 *
At a glance
- Originator Jiangsu Hengrui Medicine Co.
- Class Anti-inflammatories; Antirheumatics
- Mechanism of Action Janus kinase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Rheumatoid arthritis
Most Recent Events
- 01 Aug 2016 Jiangsu HengRui Medicine initiates a phase I pharmacokinetics trial in Healthy volunteers in China (PO, Tablet) (NCT02892370)
- 24 Jan 2016 Jiangsu HengRui Medicine plans a phase I trial for Rheumatoid arthritis in China (NCT02665910)
- 01 Apr 2015 Phase-I clinical trials in Rheumatoid arthritis (In volunteers) in China (PO) (NCT02423538)